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Background: At least 30% of patients with primary resectable non-small cell lung cancer (NSCLC) will experience a relapse in their
disease within 5 years following definitive treatment. Clinicopathological predictors have proved to be suboptimal in identifying
high-risk patients. We aimed to establish whether inflammation-based scores offer an improved prognostic ability in terms of
estimating overall (OS) and recurrence-free survival (RFS) in a cohort of operable, early-stage NSCLC patients.
Methods: Clinicopathological, demographic and treatment data were collected prospectively for 220 patients operated for
primary NSCLC at the Hammersmith Hospital from 2004 to 2011. Pretreatment modified Glasgow Prognostic Score (mGPS),
neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were tested together with established prognostic
factors in uni- and multivariate Cox regression analyses of OS and RFS.
Results: Half of the patients were male, with a median age of 65. A total of 57% were classified as stage I with adenocarcinoma
being the most prevalent subtype (60%). Univariate analyses of survival revealed stage (Po0.001), grade (P¼ 0.02), lymphovascular
(LVI, P¼ 0.001), visceral pleural invasion (VPI, P¼ 0.003), mGPS (P¼ 0.02) and NLR (P¼ 0.04) as predictors of OS, with stage
(Po0.001), VPI (P¼ 0.02) and NLR (P¼ 0.002) being confirmed as independent prognostic factors on multivariate analyses. Patients
with more advanced stage (Po0.001) and LVI (P¼ 0.008) had significantly shorter RFS.
Conclusions: An elevated NLR identifies operable NSCLC patients with a poor prognostic outlook and an OS difference of almost
2 years compared to those with a normal score at diagnosis. Our study validates the clinical utility of the NLR in early-stage
NSCLC.
Non-small cell lung cancer (NSCLC) accounts for 80% of primary
bronchogenic carcinomas (Govindan et al, 2006) and leads the
ranking of cancer-related mortality in the western world (Siegel
et al, 2012). The prognosis of NSCLC is however stage dependent
and only patients who present with early-stage disease, adequate
pulmonary reserve and preserved performance status are candi-
dates for resection, with 5-year survival rates ranging from 70% to
80% (Sakurai et al, 2010) in stage IA to only 30% in stage IIIA
(Goya et al, 2005) disease. Recently, increasing research efforts
have been directed towards the identification of clinical, patholo-
gical and biologic factors that can identify the 30% of patients with
early-stage disease who will experience tumour recurrence despite
adequate radical treatment. As recurrence is a major determinant
of patient mortality, the prospect of predicting disease relapse at
presentation might result in an improved treatment allocation such
that patients at high risk of recurrence may be offered adjuvant
therapies following radical surgery. In this context, previous studies
have identified clinicopathological features such as larger tumour
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size, the presence of lymphovascular (LVI) (Lopez Guerra et al,
2013) or visceral pleural invasion (VPI) (Fibla et al, 2012) as
adverse prognostic traits in early-stage NSCLC. However, conflict-
ing results emerging from independent studies have cast doubts
upon the reliability of these prognostic factors (Hung et al, 2007).
More recent studies have focussed on the differential protein
expression profile discriminating recurrent from non-recurrent
NSCLC. For example, a distinct upregulation of the mammalian
target of rapamycin (m-TOR) has emerged as a peculiar trait
associated with disease recurrence in independent cohorts (Dhillon
et al, 2010; Gately et al, 2012).
Systemic inflammation represents an area of growing interest in
the management and prognostic assessment of solid tumours. It
has been shown that most of the systemic symptoms relating to the
presence of cancer including weight loss, anorexia, cachexia and
anaemia are inflammatory driven and result from a condition of
systemic cytokine excess that can be either triggered by the
tumour itself or as part of the host’s innate response against cancer
(Moore et al, 2010).
A subclinical inflammatory diathesis associated with hypoalbu-
minaemia, raised C-reactive protein (CRP) and derangements in
the full blood count such as lymphopenia combined with reactive
neutrophilia and thrombocytosis, are known independent progno-
stic factors for a wide variety of solid tumours (McMillan, 2012).
Prognostic indices based on such laboratory parameters, including
the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte
ratio (PLR) and the modified Glasgow Prognostic Score (mGPS),
which combines hypoalbuminaemia and elevated CRP in a 3-tiered
prognostic model, have emerged as objective, inexpensive
and stage-independent predictors of survival in cancer (Proctor
et al, 2011).
There is mounting evidence supporting a prognostic role for the
NLR (Yao et al, 2012), PLR (Arrieta et al, 2010) and mGPS (Forrest
et al, 2005) in NSCLC. However, most of the studies have focussed
on inoperable NSCLC a patient subgroup where cancer cachexia
and poor performance status are far more prevalent than in early-
stage disease (Forrest et al, 2004, 2005; Giannousi et al, 2012).
Moreover, studies investigating the prognostic impact of systemic
inflammation in early NSCLC were conducted in Asian popula-
tions (Tomita et al, 2011, 2012), where inherent differences exist in
terms of molecular features (Sequist et al, 2007) and survival
outcomes compared with western populations (Ou et al, 2009).
Following on from our previous experience in hepatocellular
carcinoma, where we validated a new inflammation-based index as
a stage-independent predictor of survival (Pinato et al, 2012c);
here, we have evaluated and compared the prognostic value of a
panel inflammatory biomarkers such as NLR, PLR and mGPS in a
western population with resectable NSCLC.
MATERIALS AND METHODS
Patient population. A series of 220 consecutive patients who
underwent surgical treatment for primary NSCLC at Imperial
College NHS Trust from 2004 to 2011 were included in a
prospectively maintained database. Patients with evidence of an
ongoing systemic inflammatory reaction (i.e., active infection or
the presence of chronic inflammatory conditions) were excluded.
Histological subclassification, grade, pathological stage according
to the TNM Classification (7th edition) (Sobin et al, 2009) and the
presence of adverse features such as lymphovascular, pleural
invasion or evidence of residual tumour at the resection margin
were confirmed following archival haematoxylin and eosin slides
review by a consultant histopathologist with expertise in lung
pathology (FM). Complete clinical and follow-up information
including patient’s demographics, performance status and
complete preoperative blood picture were recorded. Tumour
recurrence during routine post-surgical follow-up was recorded.
Overall (OS) and recurrence-free survival (RFS) times were
calculated from the time of surgery. Inflammation-based prog-
nostic scores were calculated on preoperative blood tests as
previously described (Pinato et al, 2012c). Platelet-to-lymphocyte
ratio and NLR were derived by respectively dividing either platelet
or neutrophil absolute counts with the total lymphocyte count.
A resulting ratio of 4300 was used to define an elevated PLR
whereas a cutoff point of 45 was used to define an elevated NLR
in keeping with the previously published literature (Pinato et al,
2012a). The mGPS was computed based on serum albumin and
CRP levels. Briefly, patients with both normal albumin
(435 g l 1) and CRP (o10mg l 1) concentrations were scored
as 0. Patients in whom only one of these abnormalities was present
were allocated a score of 1, while those with both abnormal CRP
and albumin were given a score of 2. The study was approved by
the local Ethical Committee and conducted in accordance with the
principles of the Declaration of Helsinki.
Statistical analysis. The presence of significant associations
between clinico-pathological variables was determined by means
of Chi-square or Fisher’s exact test as appropriate. Kaplan–Meier
statistics and log-rank test were used to study the impact of the
different clinical factors associated with OS and RFS on univariate
analysis, with significant variables (Po0.05) being further tested
on a multivariate stepwise backward Cox regression model
to validate their independent prognostic value. Variables with a
P-value of greater than 0.10 were removed from the model.
A P-value of o0.05 was taken to be significant. All statistical
analysis was conducted using SPSS statistical package 19.0 (SPSS
Inc., Chicago, IL, USA).
RESULTS
Clinicopathologic profile of patients. The baseline patient
characteristics are shown in Table 1. A total of 220 subjects were
identified, 50% males with a median age of 65 years. All patients
had a Karnofsky performance status of X90 and adequate
pulmonary reserve with FEV1 values 41.5 l assessed before
surgery. Primary lung adenocarcinoma was the most prevalent
histotype (60%) followed by squamous cell carcinoma (24%).
Pathological examination revealed 57% of the patients being
classified as stage I. Lymphatic diffusion to N1 nodes was present
in 17% of the patients, while 6% had positive N2 nodes. N3
diffusion was found in 1% of the patients. According to clinical
criteria, a total of 15 patients received adjuvant radiotherapy
following radical surgery, while systemic chemotherapy was
administered in 16 subjects. Combined adjuvant chemo-
radiotherapy was initiated in eight subjects. The most
commonly prescribed chemotherapy regimen was three-weekly
carboplatin AUC 5 and gemcitabine 1000mgm 2 days 1 and 8 of
each 21-day cycle for 4 cycles (50%), followed by cisplatin-based
regimens either in combination with gemcitabine (25%) or
pemetrexed (25%).
On the basis of the preoperative complete blood picture, 65
patients (32%) were hypoalbuminaemic (median 37 g l 1, range
19–50 g l 1) while 66 (31%) had a CRP of410mg l 1 (median 5,
range 0–229mg l 1). The mGPS could be reconstructed in 200
patients due to missing preoperative CRP (n¼ 8) or albumin
values (n¼ 12). An abnormal mGPS (score 1–2) was found in 68
patients (31%). An NLR of 45 was found in 21 patients (10%),
while only 8 patients (3%) had a PLR of 4300. Patients with
advanced mGPS were more likely to be have Hb values o12
(Po0.001), less differentiated tumours (P¼ 0.006) with a higher
proportion of pleural invasion (P¼ 0.03). Patients with an elevated
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NLR were more likely to be anaemic (P¼ 0.02). Among patients
with an NLR of 45 at diagnosis, a total of two patients received
adjuvant treatments consisting of four cycles of cisplatin/etoposide
chemotherapy in one case and post-operative radiation therapy in
the second.
Inflammation-based indices and survival. At the end of
observation (September 2012), 51 patients (23%) had documented
evidence of disease relapse and 61 had died (28%). The median OS
of the entire cohort was 13 months (range 1–87 months) while the
median RFS was 11 months (range 1–87 months). In total, 114
patients (52%) had a documented follow-up period extending
beyond 12 months from diagnosis.
Univariate analyses revealed pTNM stage (o0.001), tumour
grade (P¼ 0.01), the presence of lymphovascular (P¼ 0.001),
pleural invasion (P¼ 0.003), NLR45 (P¼ 0.04, Figure 1A) and
advanced mGPS (P¼ 0.02, Figure 1B) as significant predictors of
OS. Multivariate analysis confirmed pTNM stage (Po0.001), the
presence of pleural invasion (P¼ 0.02) and NLR45 (P¼ 0.002) as
independent risk factors predicting patients’ mortality (Table 2).
Patients in whom the NLR was45 had a median OS of 22 months
(95% confidence interval (CI) 15–29 months) while patients with
NLRo5 had a median OS value of 45 months (95% CI 36–54
months). When stratified according to the mGPS, median OS was
50 months for mGPS 0 (95% CI 37–62 months), 23 months for
mGPS 1 (95% CI 10–36 months) and 44 months for mGPS 2
(95%CI 6.8–81). Neither mGPS (P¼ 0.21), NLR (P¼ 0.63) nor
PLR (P¼ 0.54) predicted shorter RFS after surgery. Significant
predictors of tumour relapse included pTNM stage (Po0.001) and
the presence of LVI (P¼ 0.008).
DISCUSSION
The connection between inflammation and cancer dates back to
the origin of cellular pathology itself, when Rudolf Virchow first
hypothesised a pathogenic role for the immune infiltrate
commonly found adjacent to most neoplastic tissues (Balkwill
and Mantovani, 2001). After almost two centuries, mechanistic
studies have provided solid evidence to support the pathogenic and
prognostic importance of a pro-inflammatory tumour microenvir-
onment, which is currently considered as a hallmark of cancer
progression (Hanahan and Weinberg, 2011).
Chronic inflammation predates the clinical onset of NSCLC
(O’Callaghan et al, 2010) and the biochemical ‘cross-talk’ between
inflammatory cells and the growing neoplastic clone can influence
tumour cell survival acting on immune-evasion systems and by
enhancing angiogenesis (Bremnes et al, 2011). The systemic effects
of cancer-related inflammation can be easily quantified using
routinely available blood parameters such as NLR, PLR and mGPS,
all of which have been explored as prognostic traits in NSCLC
(Forrest et al, 2005; Arrieta et al, 2010; Tomita et al, 2012).
In our study, we assessed all three parameters to evaluate
whether the presence of a subclinical systemic inflammatory
reaction before definitive treatment could better identify patients
who would have inferior survival outcomes after surgery.
Strikingly, we found that the NLR was the only inflammation-
based score with independent prognostic prediction on OS.
In our study, the first to explore the prognostic performance of
the mGPS in early-stage NSCLC, the score demonstrated
suboptimal discriminatory ability, with patients grouped as being
of intermediate risk (i.e., mGPS 1) not differing significantly from
patients of poor risk (i.e., mGPS 2) in terms of OS. A number of
studies have confirmed the mGPS as a valuable and objective tool
to assess patient’s prognosis in advanced NSCLC (Forrest et al,
2005; Giannousi et al, 2012; Leung et al, 2012), with non-inferior
accuracy to that of more established predictors such as
Table 1. General characteristics of the patient population
Baseline characteristic n¼220 (%)
Gender
Male 110 (50)
Female 110 (50)
Age, years
o65 115 (53)
X65 105 (47)
Tumour size, cm
o5.0 187 (85)
X5.0 33 (15)
pTNM stage
Ia 76 (34)
Ib 50 (23)
IIa 45 (21)
IIb 20 (9)
IIIa 29 (13)
Tumour grade
Well differentiated 43 (20)
Moderately differentiated 110 (50)
Poorly differentiated 67 (30)
Histological subtype
Adenocarcinoma 132 (60)
Squamous cell carcinoma 53 (24)
Adeno-squamous carcinoma 8 (4)
Typical carcinoid 14 (6)
Pleomorphic carcinoma 6 (3)
Large cell lung carcinoma 3 (1)
Undifferentiated carcinoma 4 (2)
Lymphovascular invasion
Absent 120 (56)
Present 100 (44)
Pleural invasion
Absent 176 (80)
Present 44 (20)
Resection margins
Clear 189 (86)
Involved 31 (14)
Surgical treatment
Wedge resection 51 (23)
Lobectomy 158 (71)
Bi-lobectomy 11 (6)
Albumin, g l1
435 140 (68)
o35 65 (32)
Haemoglobin, gdl1
412.0 165 (75)
o12.0 55 (25)
White cell count, 109 l1
o11.0 198 (90)
411.0 22 (10)
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performance status (Forrest et al, 2004). However, the lack of
reproducibility that we found seems to suggest that the mGPS is a
stage-dependent prognostic factor in NSCLC, as a likely result of
worsening cachexia in advanced tumours, that is associated with
hypoalbuminaemia and elevated CRP (Wallengren et al, 2013).
The same is not true for the NLR, whose prognostic power is
apparent in both localised (Tomita et al, 2011, 2012) and
metastatic cases of NSCLC (Cedres et al, 2012; Yao et al, 2012).
In our study, the first to validate the NLR as a prognostic
marker in early-stage NSCLC, we confirmed that an elevated NLR
identifies patients with a poor prognostic outlook and a survival
difference of almost 2 years compared to those with a normal score
at diagnosis. Interestingly, such an effect on patient survival is
independent of the tumour stage or other adverse pathological
features including grade, LVI or VPI. Our results that confirm the
accuracy of NLR as a prognostic predictor in early-stage NSCLC in
a western patient group are consistent with the results obtained
from an Asian population of 284 consecutive patients also with
early-stage NSCLC (Tomita et al, 2011). This similarity in the
findings comes despite the fact that the distribution of risk factors,
pathogenic molecular alterations and clinical outcome are notably
different in an Asian patient group.
In our comparative analysis of prognostic scores, we also tested
the PLR, whose role in predicting patient’s survival had not been
taken into consideration before in NSCLC. In our study, only a
limited fraction of patients had an elevated PLR, with no
significant impact on survival. An abnormal PLR has been
previously noted to associate with increased risk of grade III/IV
toxicity from systemic treatment in advanced NSCLC (Arrieta et al,
2010). Whether the PLR may have any prognostic role in
inoperable tumours remains to be ascertained.
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Figure 1. Kaplan–Meier curve analysis showing the difference in
median OS for patients with primary operable NSCLC categorised
according to their pretreatment NLR (A) and mGPS, where patients
are categorised in low, intermediate or poor risk (mGPS of 0, 1 and 2,
respectively) (B). .
Table 2. Clinicopathological predictors of overall survival
Overall survival
Univariate analysis Multivariate analysis
Variable N¼220
Hazard
ratio
(95% CI) P-value
Hazard
ratio
(95% CI) P-value
pTNM stage
I/II/III 126/65/29 1.4 (1.2–1.6) o0.001* 1.4 (1.2–1.7) o0.001*
Grade
Good/
Moderate/
Poor
43/110/67 1.6 (1.1–2.3) 0.02*
Lymphovascular invasion
Absent/
Present
120/100 2.5 (1.4–4.3) 0.001*
Pleural invasion
Absent/
Present
176/44 2.3 (1.3–4.1) 0.003* 2.2 (1.2–3.9) 0.02*
Resection margin
Clear/
involved
189/31 0.8 (0.4–1.7) 0.64
NLR
o5/45 198/21 2.3 (1.0–5.0) 0.04* 3.8 (1.6 –8.9) 0.002*
PLR
o300/4300 211/8 1.6 (0.6–5.6) 0.32
mGPS
0/1/2 131/39/29 1.5 (1.0–2.0) 0.02*
Abbreviations: CI¼ confidence interval; mGPS¼modified Glasgow Prognostic Score;
NLR¼ neutrophil-to-lymphocyte ratio; PLR¼platelet-to-lymphocyte ratio; pTNM¼
Pathological Tumour Node Metastasis stage according to the 7th Edition of the TNM
Classification. Associations reaching statistical significance (Po0.05) are marked with an
asterisk (*).
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This is not the first study to support the prognostic validity of
the systemic inflammatory response in cancer. In a previous study
involving 412 000 patients, the NLR was found as a significant
and accurate predictor of cancer-specific survival, independently of
histotype and stage (Proctor et al, 2012). This observation follows
growing evidence from a number of smaller, mostly single
institution-based studies, which independently confirmed a prog-
nostic role for inflammation-based indices in thoracic (Pinato et al,
2012a), gastrointestinal (Sharma et al, 2008b; Pinato et al, 2012b,
2012c; Wang et al, 2012), genitourinary malignancies (Hilmy
et al, 2006; Ramsey et al, 2007) as well as in many others
(Hilmy et al, 2006; Sharma et al, 2008a; Mohamed et al, 2014;
Pinato et al, 2014). More recent evidence has shown that resolution
of the systemic inflammatory response may reflect disease-
modulating effects from locoregional and systemic anticancer
therapies and predict for survival benefit from treatment (Kao et al,
2010; Chua et al, 2012; Pinato and Sharma, 2012).
The biological grounds justifying a prognostic role for systemic
inflammation are however yet to be fully elucidated. It is well
established that the symptomatic burden that is typically associated
with progressive malignant disease specifically anorexia, weight
loss, muscle wasting and adipose tissue depletion are part of a
complex paraneoplastic derangement in metabolism driven by the
excessive secretion of pro-inflammatory cytokines such as
interleukin (IL) 6 (Batista et al, 2013), IL-8 and tumour necrosis
factor-a (TNF-a) (Esper and Harb, 2005). Some of these mediators
such as IL-6 retain direct antiapoptotic as well as pro-angiogenic
effects, conferring survival advantage to proliferating tumour cells
and promoting resistance to cytotoxic therapies (Guo et al, 2012).
Moreover, the effects of pro-inflammatory cytokine excess,
whether directly produced by the tumour or as part of the host’s
innate response, can exert immunomodulatory effects by suppres-
sing specific antitumour immune mechanisms (Elkord et al, 2010).
T-cell function impairment, often paralleled by relative lympho-
penia in the full blood count, is at least in part responsible for an
increase in the NLR (Ray-Coquard et al, 2009).
To conclude, our study has validated the NLR as the only
inflammation-based prognostic score in operable NSCLC. Inter-
estingly, our study confirms TNM stage and VPI as predictors of
OS, while stage and LVI emerged as risk factors for shortened time
to relapse. Given the prospective nature of our study that included
unselected consecutive referrals, the significant proportion of
patients with o12 months follow-up, amounting to 48%, should
be acknowledged as a limitation to our survival analysis,
warranting independent validation of our findings in a separate
data set. However, the level of statistical significance achieved for
the prognostic traits tested in our series leaves little doubt about the
reliability and reproducibility of our findings. The NLR is a proven
objective, reproducible and inexpensive predictor of survival in
both operable and advanced stage NSCLC and consideration
should be given for its routine clinical use.
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